Recombinant interferon-beta therapy and neuromuscular disorders

Journal of Neuroimmunology

Volumn 212, Issue 1-2, 2009, Pages 132-141

  Stübgen, Joerg Patrick ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

IFN ; Myasthenia gravis; Myopathy; Neuropathy; Recombinant interferon beta

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; METHOTREXATE; PLACEBO; RECOMBINANT BETA INTERFERON;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL STUDY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; FOLLOW UP; GENETIC PREDISPOSITION; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; INCLUSION BODY MYOSITIS; INFLAMMATORY DISEASE; ISCHEMIA; MICROTHROMBUS; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOPATHY; MYOSITIS; NEURITIS; NEUROMUSCULAR DISEASE; NEUROPATHY; NONHUMAN; POLYMYOSITIS; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; RHABDOMYOLYSIS; SKIN INFLAMMATION; SKIN NECROSIS; VASCULITIS;

ANIMALS; AUTOIMMUNITY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GUILLAIN-BARRE SYNDROME; HUMANS; INTERFERON TYPE I, RECOMBINANT; INTERFERON-BETA; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYOSITIS, INCLUSION BODY; NEUROMUSCULAR DISEASES; POLYMYOSITIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 67649887325     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.04.015     Document Type: Article

References (167)

1. Anlar O., Tombul T., and Kisli M. Peripheral sensory and motor abnormalities in patients with multiple sclerosis. Electromyogr. Clin. Neurophysiol. 43 (2003) 349-351
2. Baker H.W., Balla J.I., Burger H.G., Ebeling P., and Mackay I.R. Multiple sclerosis and autoimmune diseases. Aust. N.Z. J. Med. 2 (1972) 256-260
3. Balachandran S., Kim C.N., Yeh W.C., Mak T.W., Bhalla K., and Barber G.N. Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling. EMBO J. 17 (1998) 6888-6902
4. Balachandran S., Roberts P.C., Kipperman T., Bhalla K.N., Compans R.W., Archer D.R., and Barber G.N. Alpha/beta interferons potentiate virus-induced apoptosis through activation of FADD/capsase-8 death signaling pathway. J. Virol. 74 (2000) 1513-1523
5. Barcellos L.F., Kamdar B.B., Ramsey P.P., DeLoa C., Lincoln R.R., Caillier S., Schmidt S., Haines J.L., Pericak-Vance M.A., Oksenberg J.R., and Hauser S.L. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol. 5 (2006) 924-931
6. Biron C.A., Ngyuyen K.B., Pien G.C., Cousens L.P., and Salazar-Mather T.P. Natural killer cells in antiviral-defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17 (1999) 189-220
7. Blake G., and Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment. Neurology 49 (1997) 1747-1748
8. Borg F., and Isenberg D.A. Syndromes and complications of interferon therapy. Curr. Opin. Rheumatol. 19 (2007) 61-66
9. Braun D., Caramalho I., and Demengeot J. IFNα/β enhances BCR-dependent B cell responses. Int. Immunol. 14 (2002) 411-419
10. Broadley S.A., Deans J., Sawcer S.J., Clayton D., and Compston D.A. Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 123 (2000) 1102-1111
11. Calabresi P.A., Tranquill L.R., Dambrosia J.M., Stone L.A., Maloni H., Bash C.N., Frank J.A., and McFarland H.F. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b. Ann. Neurol. 41 (1997) 669-674
12. Capasso M., Caulo M., De Luca G., Magarelli N., and Lugaresi A. Mononeuropathy following subcutaneous interferon-β injection. J. Neurol. 253 (2006) 961-962
13. Choi Y.C., and Dalakas M.C. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 54 (2000) 65-71
14. Choudhary P.P., Thompson N., and Hughes R.A. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. 242 (1995) 252-253
15. Clerico M., Contessa G., and Durelli L. Interferon-beta 1a for the treatment of multiple sclerosis. Expert Opin. Biol. Ther. 7 (2007) 535-542
16. Cocco E., Mamusa E., Carboni N., Marrosu G., Vannelli A., Mascia M.G., Sirca A., and Marrosu M.G. Treatment of refractory chronic demyelinating polyneuropathy with interferon β1b. J. Neurol. 252 (2005) 1420-1422
17. Collard R.C., Koehler P.M., and Mattson D.H. Frequency and significance of antinuclear antibodies in multiple sclerosis. Neurology 49 (1997) 857-861
18. Colosimo C., Pozzilli C., Frontoni M., Farina D., Koudriavtseva T., Gasperini C., Salvetti M., and Valesini G. No increase of serum autoantibodies during therapy with recombinant human interferon-beta1a in relapsing-remitting multiple sclerosis. Acta Neurol. Scand. 96 (1997) 372-374
19. Confalonieri P., Bernasconi P., Megna P., Galbiati S., Cornelio F., and Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J. Neuropathol. Exp. Neurol. 59 (2000) 164-169
20. Conrad B. Potential mechanisms of interferon-alpha induced autoimmunity. Autoimmunity 36 (2003) 519-523
21. Coppola G., Lanzillo R., Florio C., Orefice G., Vivo P., Ascione S., Schiavone V., Pagano A., Vacca G., De Michele G., and Morra V.B. Long-term clinical experience with weekly interferon beta-1a in relapsing multiple sclerosis. Eur. J. Neurol. 13 (2006) 1014-1021
22. Corssmit E.P., Heijligenberg R., Hack C.E., Endert E., Sauerwein H.P., and Romijn J.A. Effects of interferon-alpha (IFN-alpha) administration on leucocytes in healthy humans. Clin. Exp. Immunol. 107 (1997) 359-363
23. Corssmit E.P., de Metz J., Sauerwein H.P., and Romijn J.A. Biologic responses to IFN-alpha administration in humans. J. Interferon Cytokine Res. 20 (2000) 1039-1047
24. Costello F. Myasthenia gravis and multiple sclerosis: a review of the ocular manifestations. Insight 31 (2006) 19-22
25. Couratier P., Boukhris S., Magy L., Traoré H., and Vallat J.M. Involvement of the peripheral nervous system in multiple sclerosis. Rev. Neurol. 160 (2004) 1159-1162
26. Cousens L.P., Orange J.S., Su H.C., and Biron C.A. Interferon-α/β inhibition of interleukin-12 and interferon-γ production in vitro and endogenously during viral infection. Proc. Natl. Acad. Sci. 94 (1997) 634-639
27. Créange A. A role for interferon-beta in Guillain-Barré syndrome?. BioDrugs 14 (2000) 1-11
28. Créange A., and Lefaucheur J.P. Focal neuropathy associated with cutaneous necrosis at the site of interferon-β injection for multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 68 (2000) 395
29. Créange A., Lerat H., Meyrignac C., Degos J.D., Gherardi R.K., and Cesaro P. Treatment of Guillain-Barré syndrome with interferon-β. Lancet 352 (1998) 368-369
30. De Keyser J. Autoimmunity in multiple sclerosis. Neurology 38 (1988) 371-374
31. De Luca G., Lugaresi A., Iarlori C., Marzoli F., Uncini A., and Gambi D. Interferon beta normalizes suppressor cell function in dysimmune neuropathies. J. Neuroimmunol. 82 (1998) 1-4
32. Dionisiotis J., Zoukos Y., and Thomaides T. Development of myasthenia gravis in two patients with multiple sclerosis following interferon β treatment. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1079
33. Di Trapani G., Carnevale A., Cioffi R.P., Massaro A.R., and Profice P. Multiple sclerosis associated with peripheral demyelinating neuropathy. Clin. Neuropathol. 15 (1996) 135-138
34. Domanski P., Witte M., Kellum M., Rubinstein M., Hackett R., Pitha P., and Colamonici O.R. Cloning and expression of the long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J. Biol. Chem. 270 (1995) 21606-21611
35. Dressel A., and Beuche W. Interferon β-1a treatment of corticosteroid sensitive polymyositis. J. Neurol. Neurosurg. Psychiatry 72 (2002) 676
36. Durelli L., Ferrero B., Oggero A., Verdun E., Bongioanni M.R., Gentile E., Isoardo G.L., Ricci A., Rota E., Bergamasco B., Durazzo M., Saracco G., Biava M.A., Brossa P.C., Giorda L., Pagni R., and Aimo G. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J. Neurol. Sci. 162 (1999) 74-83
37. Dusheiko G.M. Interferon α: biology, pharmacology and therapy for chronic viral hepatitis. In: Thomson A.W., and Lotze M.T. (Eds). The Cytokine Handbook (2003), Academic Press, Amsterdam 1233-1254
38. Edwards L.J., and Constantinescu C.S. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult. Scler. 10 (2004) 575-581
39. Ekstein D., Linetsky E., Abramsky O., and Karussis D. Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis. Neurology 65 (2005) 456-458
40. Elgart G.W., Sheramata W., and Ahn Y.S. Cutaneous reactions to recombinant human interferon beta-1b; the clinical and histological spectrum. J. Am. Acad. Dermatol. 37 (1997) 553-558
41. Esper D.H., and Harb W.A. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr. Clin. Pract. 20 (2005) 369-376
42. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 (1998) 1491-1497
43. Farrar J.D., and Murphy K.M. Type I interferons and T helper development. Immunol. Today 21 (2000) 484-489
44. Fawaz L.M., Sharif-Askari E., and Menezes J. Upregulation of NK cytotoxic activity via IL-15 induction by various viruses: a comparative study. J. Immunol. 163 (1999) 4473-4480
45. Feldman D., Goldstein A.L., Cox D.C., and Grimley P.M. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2′,5′ oligoadenylate synthetase induction. Lab. Invest. 58 (1988) 584-589
46. Fowler C.J., and Gilliat R.W. Conduction velocity and conduction block in experimental ischaemic nerve injury. J. Neurol. Sci. 52 (1981) 221-238
47. Gallardo E., de Andres I., and Illa I. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J. Neuropathol. Exp. Neurol. 60 (2001) 847-855
48. Gao Y.X., Li S.L., Han X.Z., Sun Y., and Yao C.M. Therapeutic mechanisms of interferon-beta and intravenous immunoglobulin for experimental peripheral neuropathy. Zhonghua Er Ke Za Zhi 45 (2007) 574-578
49. Garg N., Zivadinov R., Ramanathan M., Vasiliu I., Locke J., Watts K., Lema J., Rajeswary J., Munschauer F.E., Ambrus J., and Weinstock-Guttman B. Clinical and MRI correlates of autoreactve antibodies in multiple sclerosis patients. J. Neuroimmunol. 187 (2007) 159-165
50. Garlepp M.J., and Mastaglia F.L. Inclusion body myositis: new insights into pathogenesis. Curr. Opin. Rheumatol. 20 (2008) 662-668
51. Goodkin D.E., and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 54 (2000) 2352 (Abstract)
52. Gorson K., Hughes R., Cros D., Pollard J., Vallat J., Riester K., Davar G., Dawson K., and Sandrock A. Efficacy of interferon beta-1a in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Abstract [P07.101], 60th Annual Meeting, American Academy of Neurology, Chicago, April 12-19 (2008)
53. Grana E.A., and Kraft G.H. Electrodiagnostic abnormalities in patients with multiple sclerosis. Arch. Phys. Med. Rehabil. 75 (1994) 778-782
54. Greenberg S.A. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology 69 (2007) 2008-2019
55. Greenberg S.A. Inclusion body myositis: review of recent literature. Curr. Neurol. Neurosci. Rep. 9 (2009) 83-89
56. Greenberg S.A., Sanoudou D., Haslett J.N., Kohane I.S., Kunkel L.M., Beggs A.H., and Amato A.A. Molecular profiles of inflammatory myopathies. Neurology 59 (2002) 1170-1182
57. Greenberg S.A., Pinkus J.L., Pinkus G.S., Burleson T., Sanoudou D., Tawil R., Barohn R.J., Saperstein D.S., Briemberg H.R., Ericsson M., Park P., and Amato A.A. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57 (2005) 664-678
58. Hadden R.D., Sharrack B., Bensa S., Soudain S.E., and Hughes R.A. Randomized trial of interferon beta-1a in chronic inflammatory polyradiculoneuropathy. Neurology 53 (1999) 57-61
59. Harada H., Tamaoka A., Kohno Y., Mochizuki A., and Shoji S. Exacerbation of myasthenia gravis in a patient after interferon-β treatment for chronic active hepatitis C. J. Neurol. Sci. 165 (1999) 182-183
60. Hartung H.P., Reiners K., Schmidt B., Stoll G., and Toyka K.V. Serum inter-leukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann. Neurol. 30 (1991) 48-53
61. Hasson J., Terry R.D., and Zimmermann H.M. Peripheral neuropathy in multiple sclerosis. Neurology 8 (1958) 503-510
62. Henderson R.D., Bain C.J., and Pender M.P. The occurrence of autoimmune diseases in patients with multiple sclerosis. J. Clin. Neurosci. 7 (2000) 434-437
63. IFNβ Multiple Sclerosis Study Group. Interferon beta-1b in effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNβ Multiple Sclerosis Study Group. Neurology 43 (1993) 655-661
64. Iguchi H., Kishi M., Fujioka T., Wakata N., and Kinoshita M. Polymyositis after interferon beta treatment of chronic hepatitis type C. Rinsho Shinkeigaku 36 (1996) 22-24
65. Inagaki H., Matsushima Y., Ohshima M., and Kitagawa Y. Interferons suppress mitochondrial gene transcription by depleting mitochondrial transcription factor A (mt TFA). J. Interferon Cytokine Res. 17 (1997) 263-269
66. Ioannou Y., and Isenberg D.A. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 43 (2000) 1431-1442
67. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndom R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., and Whitham R.H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39 (1996) 285-294
68. Jensen M.A., Arnason B.G., Toscas A., and Noronha A. Global inhibition of IL-2 and IFN-gamma secreting T cells precedes recovery from acute experimental autoimmune encephalomyelitis. J. Autoimmun. 9 (1996) 587-597
69. Karpusas M., Nolte M., Benton C.B., Meier W., Lipscomb W.N., and Goelz S. The crystal structure of human interferon β at 2.2-Å resolution. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 11813-11818
70. Kaser A., Enrich B., Ludwiczek O., Vogel W., and Tilg H. Interferon-α (IFN-α) enhances cytotoxicity in healthy volunteers and chronic hepatitis C infection mainly by the perforin pathway. Clin. Exp. Immunol. 118 (1999) 71-77
71. Kieseier B.C., Kiefer R., Gold R., Hemmer B., Willison H.J., and Hartung H.P. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30 (2004) 131-154
72. Kirkwood J.M., Bender C., Agarwala S., Tarhini A., Shipe-Spotloe J., Smelko B., Donnelly S., and Stover L. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J. Clin. Oncol. 20 (2002) 3703-3718
73. Kivisakk P., Lundahl J., von Heigl Z., and Fredrikson S. No evidence for increased frequency of autoantibodies during interferon-beta1b treatment of multiple sclerosis. Acta Neurol. Scand. 97 (1998) 320-323
74. Krause I., Valesini G., Scrivo R., and Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am. J. Med. 115 (2003) 390-397
75. Krumholz M., faber H., Steinmeyer F., Hoffmann L.A., Kümpfel T., Peilkofer H., Derfuss T., Ionescu C., Starck M., Hohlfeld R., and Meinl E. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131 (2008) 1455-1463
76. Kuhle J., Hardmeier M., and Hooghe M.D. 8-year follow-up of the European Study of Interferon beta-1-b (EUSPMS) in secondary progressive MS. Neurology 62 (2004) 489-490 (Supplement), A
77. Kuntzer T., Radziwill A.J., Lettry-Trouillat R., Naegeli C., Ochsner F., Erne B., Steck A.J., and Bogousslavsky J. Interferon-beta 1a in chronic inflammatory demyelinating polyneuropathy. Neurology 53 (1999) 1364-1365
78. Leary S.M., Miller D.H., Stevenson V.L., Brex P.A., Chard D.T., and Thompson A.J. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 60 (2003) 44-51
79. LeBon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., and Tough D.F. Type I interferons potentially enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14 (2001) 461-470
80. Lechner J., Malloth N., Seppi T., Beer B., Jennings P., and Pfaller W. IFN-alpha induces barrier destabilization and apoptosis in renal proximal tubular epithelium. Am. J. Physiol., Cell Physiol. 294 (2008) 153-160
81. Léger J.M., and Behin A. Multifocal motor neuropathy. Curr. Opin. Neurol. 18 (2005) 567-573
82. Leppert D., Waubant E., Bürk M.R., Oksenberg J.R., and Hauser S.L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann. Neurol. 40 (1996) 846-852
83. Lisak R.P. Type I interferons and chronic inflammatory demyelinating polyneuropathy: treatment or cause?. Muscle Nerve 23 (2000) 307-309
84. Lünemannn J.D., Kassim N., Zschenderlein R., Zipp F., and Schwarzenberger B. Rhabdomyolysis during interferon-β 1a treatment. J. Neurol. Neurosurg. Psychiatry 72 (2002) 274
85. Lutfalla G., Holland S.J., Cinato E., Monneron D., Reboul J., Rogers N.C., Smith J.M., Stark G.R., Gardiner K., and Morgensen K.E. Mutant U5A cells are complemented by an interferon-alpha beta subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J. 14 (1995) 5100-5108
86. Mak T.W., and Saunders M.E. The immune response. Basic and Clinical Principles (2006), Elsevier, Amsterdam 469-474
87. Markowitz C.E. Interferon-beta: mechanism of action and dosing issues. Neurology 68 Supplement 4 (2007) S8-11
88. Marrack P., Kappler J., and Mitchell T. Type I interferons keep activated T cells alive. J. Exp. Med. 189 (1999) 521-530
89. Martina I.S., van Doorn P.A., Schmitz P.L., Meulstee J., and van der Meché F.G. Chronic motor neuropathies: response to interferon-β1a after failure of conventional therapies. J. Neurol. Neurosurg. Psychiatry 66 (1999) 197-201
90. Matsuse D., Ochi H., Tashiro K., Nomura T., Murai H., Taniwaki T., and Kira J. Exacerbation of chronic inflammatory demyelinating polyradiculoneuropathy during interferon beta-1b therapy in a patient with childhood-onset multiple sclerosis. Intern. Med. 4 (2005) 68-72
91. Melstrom L.G., Melstrom Jr. K.A., Ding X.Z., and Adrian T.E. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol. Histopathol. 22 (2007) 805-814
92. Midgard R., Grønning M., Riise T., Kvåle G., and Nyland H. Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol. Scand. 93 (1996) 322-328
93. Miller F.W., Hess E.V., Clauw D.J., Hertzman P.A., Pincus T., Silver R.M., Mayes M.D., Varga J., Medsger Jr. T.A., and Love L.A. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum. 43 (2000) 243-249
94. Misawa S., Kuwabara S., Mori M., Kawaguchi N., Yoshiyama Y., and Hattori T. Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 56 (2001) 666-669
95. Misawa S., Kuwabara S., Mori M., Hayakawa S., Sawai S., and Hattori T. Peripheral nerve demyelination in multiple sclerosis. Clin. Neurophysiol. 119 (2008) 1829-1833
96. Mittag T.W., and Caroscio J. False-positive immunoassay for acetylcholine-receptor antibody in amyotrophic lateral sclerosis. N. Engl. J. Med. 302 (1980) 868
97. Montalban X. Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. Mult. Scler. 10 Supplement1 (2004) 62-64
98. Moore R.N., Larsen H.S., Horohov D.W., and Rouse B.T. Endogenous regulation of macrophage proliferative expansion by CSF-induced interferon. Science 223 (1984) 178-181
99. Nagaraju K., Casciola-Rosen L., Lundberg I., Rawat R., Cutting S., Thapliyal R., Chang J., Dwivedi S., Mitsak M., Chen Y.W., Plotz P., Rosen A., Hoffman E., and Raben N. Activation of endoplasmic reticulum stress response in autoimmune myositis: a potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 52 (2005) 1824-1835
100. Nguyen K.B., Cousens L.P., Doughty L.A., Pien G.C., Durbin J.E., and Biron C.A. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT resolves a paradox. Nat. Immunol. 1 (2000) 70-76
101. Nielsen N.M., Frisch M., Rostgaard K., Wohlfahrt J., Hjalgrim H., Koch-Hendriksen N., Melbye M., and Westergaard T. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult. Scler. 14 (2008) 823-829
102. Nobile-Orazio E., Cappellari A., and Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve 31 (2005) 663-680
103. Noronha A., Toscas A., and Jensen M.A. Interferon augments suppressor cell function in multiple sclerosis. Ann. Neurol. 27 (1990) 207-210
104. Noronha A., Toscas A., and Jensen M.A. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J. Neuroimmunol. 46 (1993) 145-154
105. Novick D., Cohen B., and Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77 (1994) 391-400
106. Ogasawara K., Hida S., Azimi N., Tagaya Y., Sato T., Yokochi-Fukuda T., Waldman T.A., Taniguchi T., and Taki S. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391 (1998) 700-703
107. Ozenci V., Kouwenhoven M., Teleshova N., Pashenkov M., Fredrikson S., and Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β. J. Neuroimmunol. 108 (2000) 236-243
108. Parry G.J., and Brown M.J. Selective fiber vulnerability in acute ischemic neuropathy. Ann. Neurol. 11 (1982) 147-154
109. Pedrol E., Grau J.M., Casademont J., Cid M.C., Masanés F., Fernandez-Sola J., and Urbano-Mårquez A. Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin. Neuropathol. 14 (1995) 179-184
110. Pirko I., Kuntz N.L., Patterson M., Keegan B.M., Weinshenker B.G., and Rodriguez M. Contrasting effects of IFN beta and IVIG in children with central and peripheral demyelination. Neurology 60 (2003) 1697-1699
111. Pogorzelski R., Baniukiewicz E., and Drozdowski W. Subclinical lesions of peripheral nervous system in multiple sclerosis patients. Neurol. Neurochir. Pol. 38 (2004) 257-264
112. Pollock M., Calder C., and Allpress S. Peripheral nerve abnormality in multiple sclerosis. Ann. Neurol. 2 (1977) 41-48
113. Polman C.H., Kappos L., Dahlke F., Graf R., Beckmann K., Bogumil T., Pozzilli C., Thompson A.J., and European Study Group on Interferon Beta-1b. Interferon beta-1b treatment does not induce autoantibodies. Neurology 64 (2005) 996-1000
114. Porrini A.M., Gambi D., and Reder A.T. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J. Neuroimmunol. 61 (1995) 27-34
115. PRISMS Study Group. Randomized, double-blind, placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352 (1998) 1498-1504
116. Pritchard J., Gray I.A., Idrissova Z.R., Lecky B.R.F., Sutton I.J., Swan A.V., Willison H.J., Winer J.B., and Hughes R.A.C. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome. Neurology 61 (2003) 1282-1284
117. Radhakrishnan R., Walter L.J., Hruza A., Reichert P., Trotta P.P., Nagabhushan T.L., and Walter M.R. Zinc mediated dimmer of human interferon-α2b revealed by X-ray crystallography. Structure 4 (1996) 1453-1463
118. Radziwill A.J., Kuntzer T., Fuhr P., and Steck A.J. Long term follow up in chronic inflammatory demyelinating polyneuropathy (CIDP) under interferon beta-1a (IFN-[beta]1a) and intravenous immunoglobulin (IVIg). J. Neurol. Neurosurg. Psychiatry 70 (2001) 273
119. Rajabally Y.A. Multifocal motor neuropathy: review of a treatable immune mediated disorder. Postgrad. Med. J. 84 (2008) 287-292
120. Ramagopalan S.V., Dyment D.A., Valdar W., Herrera B.M., Criscuoli M., Yee I.M., Sadovnick A.D., Ebers G.C., and Canadian Collaborative Study Group. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 6 (2007) 604-610
121. Rees J.H., Soudan S.E., Gregson N.A., and Hughes R.A.C. Campylobacter jejuni infection and Guillain-Barré syndrome. N. Engl. J. Med. 333 (1995) 1374-1379
122. Reis L.F., Lee T.H., and Vilcek J. Tumor necrosis factor acts synergistically with autocrine interferon-β and increases interferon-β mRNA levels in human fibroblasts. J. Biol. Chem. 264 (1989) 16351-16354
123. Remington J.S., and Merigan T.C. Resistance to virus challenge in mice infected with protozoa or bacteria. J. Biol. Exp. Biol. Med. 131 (1969) 1184-1188
124. Rio J., Tintoré M., Nos C., Téllez N., Galån I., and Montalban X. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J. Neurol. 252 (2005) 795-800
125. Rysiecki G., Gewert D.R., and Williams B.R. Constitutive expression of a 2′,5′-oligoadenylate synthetase cDNA results in increased antiviral activity and growth suppression. J. Interferon Res. 9 (1989) 649-657
126. Saida T., Tashiro K., Itoyama Y., Sato T., Ohashi Y., and Zhao Z. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 64 (2005) 621-630
127. Sarova-Pinhas I., Achiron A., Gilad R., and Lampi Y. Peripheral neuropathy in multiple sclerosis: a clinical and electrophysiologic study. Acta Neurol. Scad. 91 (1995) 234-238
128. Satoyoshi E., Kinoshita M., Nakazato H., and Saku A. Evaluation of 4 cases with clinical characteristics of myasthenia gravis and multiple sclerosis. Rinsho Shinkeigaku 15 (1975) 888-894
129. Sawaya R.A. Interferon beta for Guillain-Barré syndrome. Lancet 351 (1998) 1550-1551
130. Schaller B., Radziwill A.J., and Steck A.J. Successful treatment of Guillain-Barré syndrome with combined administration of interferon-β-1a and intravenous immunoglobulin. Eur. Neurol. 46 (2001) 167-168
131. Seyfert S., Klapps P., Meisel C., Fischer T., and Junghan U. Multiple sclerosis and other immunologic diseases. Acta Neurol. Scand. 81 (1990) 37-42
132. Shan B., Vazquez E., and Lewis J.A. Interferon selectively inhibits the expression of mitochondrial genes: a novel pathway for interferon-mediated responses. EMBO J. 9 (1990) 4307-4314
133. Sharma K.R., Saadia D., Facca A.G., Bhatia R., Ayyar D.R., and Sheremata W. Chronic demyelinating polyradiculoneuropathy associated with multiple sclerosis. J. Clin. Neuromusc. Dis. 9 (2008) 385-396
134. Shimizu H., Kataoka H., Kawahara M., Hirano M., Furiya Y., and Ueno S. Interferon causes no myasthenia in a seropositive patient with multiple sclerosis. Clin. Neurol. Neurosurg. 109 (2007) 277-278
135. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., Antonenko S., and Liu Y.J. The nature of the principal type I interferon-producing cells in human blood. Science 284 (1999) 1835-1837
136. Somani A.K., Swick A.R., Cooper K.D., and McCormick T.S. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch. Dermatol. 144 (2008) 1341-1349
137. Somer H., Muller K., and Kinnunen E. Myasthenia gravis associated with multiple sclerosis: epidemiological survey and immunological findings. J. Neurol. Sci. 89 (1989) 37-48
138. Soos J.M., and Szente B.E. Type I interferons. In: Thomson A.W., and Lotze M.T. (Eds). The Cytokine Handbook (2003), Academic Press, Amsterdam 549-566
139. Spadaro M., Amendolea M.A., Mazzucconi M.G., Fantozzi R., Di Lello R., Zangari P., and Masal G. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Mult. Scler. 5 (1999) 121-125
140. Speciale L., Saresella M., Caputo D., Ruzzante S., Mancuso R., Calvo M.G., Guerini F.R., and Ferrante P. Serum auto-antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J. Neurovirol. 6 Supplement 2 (2000) S57-61
141. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56 (2001) 1496-1504
142. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., and Schreiber R.D. How cells respond to interferons. Annu. Rev. Biochem. 67 (1998) 227-264
143. Stüve O., Dooley N.P., Uhm J.H., Antel J.P., Francis G.S., Williams G., and Yong V.W. Interferon beta-1b decreases migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann. Neurol. 40 (1996) 853-863
144. Subramaniam P.S., Cruz P.E., Hobeika A.C., and Johnson H.M. Type I interferon induction of the Cdk-inhibitor p21WAF1 is accompanied by ordered G1 arrest, differentiation and apoptosis of the Daudi B-cell line. Oncogene 16 (1998) 1885-1890
145. Tanaka N., Sato M., Lamphier M.S., Nozawa H., Oda E., Noguchi S., Schreiber R.D., Tsujimoto Y., and Taniguchi T. Type I interferons are essential mediators of apoptotic cell death in virally infected cells. Genes Cells 3 (1998) 29-37
146. The Muscle Study Group. Randomized pilot trial of βIFN1a (Avonex) in patients with inclusion body myositis. Neurology 57 (2001) 1566-1570
147. The Muscle Study Group. Randomized pilot trial of high-dose βINF-1a in patients with inclusion body myositis. Neurology 63 (2004) 718-720
148. Theofilopoulos A.N., Baccala R., Beutler B., and Kono D.H. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu. Rev. Immunol. 23 (2005) 307-336
149. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112 (1997) 1017-1021
150. Tough D.F., Borrow P., and Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272 (1996) 1947-1950
151. Tyring S.K. Interferons: biochemistry and mechanisms of action. Am. J. Obstet. Gynecol. 172 (1995) 1350-1353
152. Uzé G., Schreiber G., Piehler J., and Pellegrini S. The receptor of the type I interferon family. Curr. Top. Microbiol. Immunol. 316 (2007) 71-95
153. Vallat J.M., Hahn A.F., Léger J.M., Cros D.P., Magy L., Tabaraud F., Bouche P., and Preux P.M. Interferon beta-1a as an investigational treatment for CIDP. Neurology 60 Supplement (2003) S23-S28
154. Van den Berg-Vos R.M., Van den Berg L.H., Franssen H., Van Doorn P.A., Merkies I.S., and Wokke J.H. Treatment of multifocal motor neuropathy with interferon-β1A. Neurology 54 (2000) 1518-1521
155. Verdun E., Isoardo G., Oggero A., Ferrero B., Ghezzi A., Montanari E., Zaffaroni M., Durelli L., and Betaferon Safety Trial (BEST) Study Group. Autoantibodies in multiple sclerosis patients before and during IFNβ-1b treatment: are they correlated with the occurrence of autoimmune diseases?. J. Interferon Cytokine Res. 22 (2002) 245-255
156. Villa A.M., Garcea O., Di Egidio M., Saizar R., and Sica R.E. Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: a case report. Arq. Neuro-Psiquiatr. 62 (2004) 892-894
157. Vriesendorp F.J., Flynn R.E., Khan M., Papolla M.A., and Brod S.A. Oral administration of type I interferon modulates the course of experimental allergic neuritis. Autoimmunity 24 (1996) 157-165
158. Walsh R.J., Kong S.W., Yao Y., Jallal B., Kiener P.A., Pinkus J.L., Beggs A.H., Amato A.A., and Greenberg S.A. Type 1 interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56 (2007) 3784-3792
159. Weinberg J.M., Wolfe J.T., Sood S., Saruk M., Rook A.H., and Spiers E.M. Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature. Acta Derm.-Venerol. 77 (1997) 146-148
160. Weissman C., and Weber H. The interferon genes. Proc. Nucl. Acid Res. 33 (1986) 251-300
161. Yakushiji Y., Sotoh J., Yukitake M., Yamaguchi K., Nakamura I., Nishino I., and Kuroda Y. Interferon β-responsive inclusion body myositis in a hepatitis C virus carrier. Neurology 63 (2004) 587-588
162. Yanase N., Ohshima K., Ikegami H., and Mizuguchi J. Cytochrome c release, mitochondrial membrane depolarization, capase-3 activation, and Bax-alpha cleavage during IFN-alpha-induced apoptosis in Daudi B lymphoma cells. J. Interferon Cytokine Res. 20 (2000) 1121-1129
163. You X., Teng W., and Shan Z. Expression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha. Chin. Med. J. 112 (1999) 61-66
164. Zang Y.C., Halder J.B., Samanta A.K., Hong J., Rivera V.M., and Zhang J.Z. Regulation of chemokine receptor CCR 5 and production of RANTES and MIP-1 alpha by interferon-beta. J. Neuroimmunol. 112 (2001) 174-180
165. Zee P.C., Cohen B.A., Walczak T., and Jubelt B. Peripheral nervous system involvement in multiple sclerosis. Neurology 41 (1991) 457-460
166. Zhang X., Sun S., Hwang I., Tough D.F., and Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8 (1998) 591-599
167. Zou L.P., Ma D.H., Wei L., van der Meide P.H., Mix E., and Zhu J. IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue. J. Neurosci. Res. 56 (1999) 123-130